OSA
1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Prevail TherapeuticsOrforglipron
ResMedCPAP
ResMedNasal mask
Clinical Trials (3)
Total enrollment: 1,020 patients across 3 trials
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Start: Oct 2024Est. completion: Jan 2027600 patients
Phase 3Active Not Recruiting
Long-term Benefits of CPAP or MAD Treatment on the Sleep of OSAS Patients
Start: Jul 2022Est. completion: Oct 2026400 patients
N/ARecruiting
Nasal Pillows vs. Nasal Masks at High CPAP Pressure
Start: Aug 2011Est. completion: Dec 201220 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,020 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.